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Background: A novel reverse-phase high-performance liquid chromatography (RP-HPLC)-DAD method was
developed, validated and applied to quantify olopatadine hydrochloride in pharmaceutical products.
Methods: The RP-HPLC analyses were carried out using a mixture of 0.1% formic acid and methanol (35:65) as a
mobile phase on ZORBAX Eclipse Plus C18 (250 mm × 4.6 mm, 5 μm), with a flow rate of 1.0 mL/min and UV
detection at 300 nm. The developed method was validated as per the International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceutical for Human Use guidelines for linearity, range,
accuracy, precision, robustness, limit of detection, limit of quantitation and specificity.
Results: The validated method was applied to quantify the drug content in raw material, tablets and eye drops
which was found to be 99.36% to 101.02%, 98.99% to 100.56% and 99.09% to 100.91%, respectively.
Conclusion: The method was found to be efficient, precise, accurate, specific and economic and useful for the
routine analysis of olopatadine hydrochloride in pharmaceutical industries.
Keywords: Olopatadine hydrochloride; RP-HPLC; Pharmaceutical productsBackground
Olopatadine (OLO) is a new histamine H1 receptor-
selective antagonist, chemically, 11-((Z)-3-(dimethyl-amino)
propylidene)-6,11-dihydro-dibenz[b,e]oxepin-2-acetic acid
(Ohshima et al. 1992) (Figure 1), used to treat allergic
conjunctivitis (itching eyes) (Scoper et al. 2007; Kajita et al.
2002; McGill 2004; Takahashi et al. 2008; Ohishi et al.
1995). Very few assay methods were reported for the
analysis of olopatadine, viz. radioimmunoassay method
for humans (Tsunoo et al. 1995).
However, it had several problems, such as cross-reactivity
of metabolites and low precision, and so it was consi-
dered that plasma concentrations of olopatadine measured
by RIA needed to be confirmed by an alternative method.* Correspondence: pawanbasniwal@gmail.com
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2013High-performance liquid chromatography (HPLC) with
tandem mass spectrometry has been applied for the
determination of a number of compounds in biological
fluids (Zhu et al. 2011). Other assay methods for olopatadine
and its metabolites in human plasma by HPLC with
electrospray ionisation tandem mass spectrometry were
reported (Fujimaki et al. 2006; Fujita et al. 1999). Varghese
et al. (2011) have used 0.1% orthophosphoric acid (pH 4.5)
with triethylamine/acetonitrile (75:25) for the determin-
ation of olopatadine hydrochloride. Triethylamine should
be avoided as its addition to the mobile phase requires
longer column equilibration times, which is not advisable
for the routine use of the developed method. It occa-
sionally introduces additional problems such as erratic
baselines and poor peak shape and complicates the
preparation of the mobile phase (Synder et al. 1997). A
complicated buffer is a component of the mobile phase
for the HPLC method, which includes monobasic potas-
sium phosphate (6.8 g), 1-pentane sulphonic acid sodiumis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Figure 1 Structure of olopatadine hydrochloride.
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the pH is adjusted to 3.0 with orthophosphoric acid (Rele
and Warkar 2011). Thus, both the above methods cannot
be useful for routine analysis as tedious mobile phase
composition and problem arise from triethylamine.
Hitherto, the objective of the present research work was to
develop a simple, precise, accurate and fast reverse-phase
high-performance liquid chromatography (RP-HPLC) assay
method for the analysis of olopatadine hydrochloride in dif-
ferent pharmaceutical products including raw material, tab-
lets and eye drops, and to compare the assay results by
statistical analysis, which may be useful for routine analysis.
Methods
Instrumentation and chromatograph
The HPLC chromatograph used was Agilent Infinity 1260
series (Agilent Technologies, Inc., Santa Clara, CA, USA)
equipped with 1260 binary pump VL (400 bar), 1260 man-
ual injector (600 bar), Rheodyne 7725i seven-port sample
injection valve with 20-μL fixed loop, ZORBAX Eclipse
Plus C18 (250 mm × 4.6 mm, 5 μm), 1260 DAD VL, 20-Hz
detector, standard flow cell (10 mm, 13 μL, 120 bar),
OpenLab CDS EZChrom Ed. Workstation and syringe
(50.0 μL, FN, LC tip). All weighing for analysis was per-
formed on Shimadzu electronic analytical balance AX-200
(Kyoto, Japan). Water used for analysis was prepared by
triple distillation assembly. All dilutions, mobile phase and
other solutions that were used for the analysis were filtered
through a 0.2-μm nylon filter (Ultipor®N66 Nylon 6,6 mem-
brane, Pall Sciences, Pall India Pvt. Ltd., Mumbai, India).
Chemicals and reagent
The working standard used was OLO which was supplied
by Ranbaxy Laboratories Limited (Gurgaon, Harayana,
India) as a gift sample. Formic acid and methanol were
procured from Merck Specialties Private Limited
(Mumbai, India). The mobile phase was prepared from
the combination of formic acid (0.1%) and methanol.
Chromatography
Accurately weighed 50 mg of OLO was dissolved in 50%
aqueous methanol to prepare stock I (1,000 μg/mL) in a50-mL volumetric flask. Stock II (100 μg/mL) was prepared
from stock I, which was used to prepare further dilutions
containing 1, 5, 10, 15 and 20 μg/mL. All dilutions were fil-
tered through the 0.2-μm nylon filter (Ultipor®N66 Nylon
6,6 membrane, Pall Sciences) and chromatographed by a
set of conditions on Agilent Infinity 1260 series. The mix-
ture of 0.1% formic acid and methanol (35:65) was used as
the mobile phase for the elution of the drug on Zorbax
Eclipse Plus C18 column (250 mm × 4.6 mm, 5 μm) at
1.0 mL/min flow rate. OLO was successfully eluted at
3.77 min with a run time of 7 min, and detection was
performed using a photodiode array detector (PDA) at 300 nm.Method validation
According to the International Conference on Harmonisa-
tion of Technical Requirements for Registration of Pharma-
ceutical for Human Use (ICH) guidelines (ICH 2000a, b),
the developed method was validated to assure the reli-
ability of the results of analysis for the different parame-
ters, viz. linearity, range, accuracy, precision, robustness,
limit of quantization (LOQ), limit of detection (LOD) and
specificity. Linearity was determined by serial dilutions
(1 to 20 μg/mL) of the OLO in 50% aqueous methanol
in triplicate. The range of OLO was validated between 5
and 15 μg/mL with triplicates of dilutions. The recovery
method was used to determine the accuracy of the de-
veloped method by spiking the standard solution to the
pre-analysed samples (5, 10 and 15 μg/mL), which was
repeated six times. Repeatability and intermediate preci-
sion were studied to assure the precision of the method.
Six replicates of the standard dilution (5 μg/mL) were
chromatographed subsequently to assure repeatability,
which were further chromatographed after 5 h to assure
the stability of the drug in the solvent system. The stand-
ard dilutions were analysed by different analysts in subse-
quent days to study intermediate precision in the linearity
range. A change in temperature (20°C, 25°C and 30°C)
and acidic content of the aqueous part of the mobile phase
(5% change in 0.1% aqueous formic acid) was observed.
Different serial dilutions of OLO (0.1 to 1,000 ng/mL)
were chromatographed to calculate the signal-to-noise
ratio to determine LOD and LOQ. Alkaline-degraded
OLO samples were chromatographed to ascertain the
specificity of the developed method for OLO.Analysis of pharmaceutical products
Raw material
As per the ‘Chromatography’ subsection, the samples
of raw material have been prepared and analysed in the
set of condition of analysis, which was repeated in six
batches. The response to chromatographic analysis was
used to calculate the concentration with the help of a
regression equation.
Figure 2 Representative chromatogram (A), counterplot (B), Gaussian spectra (C), peak purity curve (D) and three-dimensional view
(E) of OLO.
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Table 1 System suitability parameters for OLO in 0.1%
formic acid and methanol (35:65) on C18 column
Parameters Value (n = 6) SD %RSD
Number of theoretical plates 8,578 42.63 1.09
Tailing factor 1.31 0.94 0.49
RT (min) 3.77 0.046 0.021
Peak purity 1 0 0
SD standard deviation, RSD relative standard deviation, RT retention time.
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Powdered tablets were weighed equivalently to 50 mg
of OLO and sonicated to dissolve the drug content in
methanol to extract the complete drug content from the
tablet powder. The sonicated solution was filtered through
Whatman filter no. 41 to remove the un-dissolved ex-
cipients of the tablet dosage form, and different serial
dilutions were prepared by subsequent dilution with 50%
aqueous methanol. All dilutions were filtered through the
0.2 μm nylon filter and chromatographed. The drug con-
tent was determined from the regression equation.
Eye drops
An accurately measured volume of ophthalmic solution
(Olodin, FDC Limited, Aurangabad, India), equivalent
to about 10 mg of OLO, was transferred to a 100 mL
163 volumetric flask and diluted with diluent to the volume.
The solution was mixed and sonicated for 10 min. An ap-
propriate dilution was prepared from the stock solution and
filtered (stock P, 100 μg/mL). Aliquots of stock P were
diluted to get sample concentrations (5, 10 and 15 μg/mL)
in the range of linearity for the developed method and
filtered through the 0.2 μm nylon filter. All these dilu-
tions were chromatographed, and the area under the
curve (AUC) of the peak of OLO was placed in the regres-
sion equation to get the concentration of the samples.
Results and discussion
Optimization of chromatography
The aim of this research work was to develop a novel
RP-HPLC method for the determination of OLO in dif-
ferent matrices by eliminating the triethylamine compo-
nent in the mobile phase, which improves the peak shape
associated with other number of troubles to the column.
Keeping the view of the results with triethylamine use
in the mobile phase, the physical properties of OLO were
used to improve the chromatographic parameters. On
the basis of the solubility of OLO, different combinations
of the mobile phase were tried to elute on C18 column.
Broadening and splitting of the peak have been seen with
the mixture of methanol and water (50:50) and the mix-
ture of acetonitrile and water (50:50). The pKa value (4.29)
has been taken into account to design the mobile phase
composition as OLO has a carboxylic group. So 0.1% for-
mic acid was added to the aqueous phase of the mixture
of acetonitrile and water (50:50), but the same broadening
of peak with a little bit splitting of peak was observed.
Tailing was found with the mixture of methanol and water
(50:50) along with the acidic content of the aqueous phase
which was improved by increasing the concentration of
methanol content in the mobile phase. A very sharp peak
shape was found with 70% content of methanol in the mo-
bile phase, but it was merging with the diluent peak when a
higher value was present at 60%. Thus, chromatographicconditions were concluded to be better than the reported
methods.
The mixture of 0.1% formic acid and methanol (35:65)
was selected to elute OLO on C18 column with 1 mL/min
flow rate, where it was eluted at 3.77 min with acceptable
peak shape and tailing factor (Figure 2A). A counterplot
of the chromatogram was able to show the exact position
of the elution point where time and wavelength cross each
other (Figure 2B). The detection wavelength was 300 nm,
which was the λmax of OLO (Figure 2C).
The peak purity of OLO in the chromatogram was 1 unit
which was supported by the peak purity curve (Figure 2D).
A three-dimensional view of the chromatogram was the
proof for no interference to the peak of OLO (Figure 2E).
System suitability parameters
Acceptable system suitability results for a chromato-
graphic run establish that the method is performing
adequately and can be used to generate reportable data. It
includes the number of theoretical plates, tailing factor,
retention time and peak purity of the analyte. The num-
ber of theoretical plates for the C18 column was 8,578
(n = 6) with an acceptable relative standard deviation
(%RSD) value of 1.09, which indicates that the column
performance was excellent. OLO should have tailing in
the chromatogram on C18 column if the mobile phase is
without diethylamine or triethylamine as it has a tertiary
amino functional group. The formic acid content of the
aqueous phase of the mobile phase was solved to have
an acceptable limit of tailing factor (1.31) with a %RSD
of 0.49. The retention time for OLO was 3.77 min in the
7 min run time of analysis. The peak purity of the OLO
was always 1 at 3.77 min (Table 1).
Method validation
A linear relationship was found between the OLO con-
centrations and the response to chromatographic analysis
which was demonstrated by high regression coefficients
(r2 = 0.999) for the concentration of 1 to 20 μg/mL and
the mean regression equation was found as AUC =
79,991X − 64,340. The working range for the drug was
selected to be 5 to 15 μg/mL. Accuracy was investigated
by the recovery of standard addition to pre-analysed
samples which was near 100% with acceptable %RSD.
Intra-day variation (repeatability) and intermediate
Table 2 Validation parameters for olopatadine hydrochloride
Parameters Valuesa ± SD, ± %RSD
Linearity 1 to 20 μg/mL
Regression equation AUC = 79,991X − 64,340
Correlation coefficient r2 = 0.999 ± 0.001, ±0.100
Range 5 to 15 μg/mL ± 1.08, ±0.51
Accuracy 100.11 ± 1.065, ±0.784
Precision
Repeatability 99.94 ± 0.742, ±0.482
Intermediate precision
Inter-day 100.08 ± 0.825, ±0.091
Analyst to analyst 99.89 ± 0.929, ±0.027
Robustness
Temperature (20°C, 25°C and 30°C) 99.91 ± 0.816, ±0.089
Formic acid concentration (±5%) 100.06 ± 0.794, ±0.296
LOQ 5 ng/mL ± 1.098, ±0.566
LOD 0.5 ng/mL ± 1.691, ±0.295
Specificity Ascertained by analysing standard
drug and degraded sample of
equivalent concentration
aMean of six replicates. SD standard deviation, RSD relative standard deviation,
AUC area under the curve, LOQ limit of quantification, LOD limit of detection.
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analysing quality control samples containing low, medium
and high concentrations of OLO.
For intra-day variation, sets of the six replicates of the
three concentrations were analysed on the same day; for
intermediate precision, the six replicates were analysed
on three different days by three different analysts. All
results of precision were between 99.89% and 100.08%
within the acceptable limits of %RSD values, and there
was no significant difference in the results of the ana-
lysis when drug samples were analysed after 5 h. The
developed method is robust when it was unaffected by
small changes in operating conditions of the analysis.
The experimental conditions were deliberately alteredTable 3 Analysis of olopatadine hydrochloride in pharmaceut
Concentration of
Batch Raw material (μg/mL) Ta
5 10 15 5
A 100.23 100.92 99.83 99.93
B 101.02 99.28 100.12 98.99
C 99.36 100.04 99.94 100.29
D 98.94 100.91 100.46 100.06
E 100.32 99.76 99.83 99.89
F 100.19 99.89 100.11 100.56
Mean 100.01 100.13 100.05 99.95
SD 0.556
SD standard deviation.at three different levels, and chromatographic response
was evaluated.
Changes in temperature of analysis time and formic
acid percent of the aqueous part of the mobile phase
were studied as robustness factors, and one factor at a
time was changed to study the effect on the result of the
method. The results of robustness vary between 99.91%
and 100.06% with less than 1 unit of the %RSD value
(Table 2). The LOD and LOQ were determined by con-
sidering the signal-to-noise ratio of 3 and 10, respec-
tively. The developed method was highly sensitive to
OLO as LOD and LOQ values were found to be 0.5 and
5 ng/mL, respectively. The method was specific to the
drug as PDA analyses proved that the peak purity for
the drug peak in a mixture of stressed samples was 1
unit. The purity threshold curve hereby indicated that the
drug peak was free from any co-eluting peak (Figure 2E).
Analysis of products
The validated chromatographic method was applied to
determine OLO in raw material, tablets and eye drops,
where six batches were prepared for each quality control
sample (5, 10, and 15 μg/mL) for all pharmaceutical
products.
OLO was determined in raw material within the range
of 99.36% to 101.02% with a standard deviation of 0.556.
In the tablet dosage form, the drug content was found to
be within the range of 98.99% to 100.56% with a standard
deviation of 0.404. In a similar fashion, the OLO content
in the eye drop was estimated to be in the range of 99.09%
to 100.91% with a standard deviation of 0.498 (Table 3).
Thus, all the pharmaceutical products have been analysed
within the acceptable limits.
Conclusion
Hence, the simple, fast, precise, accurate and novel
reverse-phase liquid chromatographic method was de-
veloped and validated according to ICH guidelines. Theical products
quality control samples (%)
blet (μg/mL) Eye drop (μg/mL)
10 15 5 10 15
99.99 100.19 100.83 99.48 100.03
99.63 99.92 100.41 100.69 100.28
100.59 100.46 99.98 100.83 99.56
100.48 100.56 99.74 99.93 99.09
99.67 99.89 100.46 100.91 100.06
100.16 100.15 100.29 100.02 100.04
100.09 100.20 100.29 100.31 99.84
0.404 0.498
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the OLO content in pharmaceutical products including
raw material, tablets and eye drops with acceptable limits.
As previous reported methods may not be applied for
routine analysis due to the use of the triethylamine
component in the mobile phase, this novel RP-HPLC
method might be applied for assays, dissolution studies,
bio-equivalence studies as well as routine analysis of
OLO in pharmaceutical industries.Competing interests
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